Compare Revvity Inc (RVTY) vs iShares 10 20 Year Treasury Bond ETF (TLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs iShares 10 20 Year Treasury Bond ETF — how do they compare? Revvity Inc trades at $154.18 (market cap $16.98B), while iShares 10 20 Year Treasury Bond ETF trades at $92.19 (market cap $11.02B). The key difference: Revvity Inc is the larger of the two by market cap, and Revvity Inc pays a 0.18% dividend while iShares 10 20 Year Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 12 Days and iShares 10 20 Year Treasury Bond ETF for 60 Days on average.
| RVTY | TLH | |
|---|---|---|
Market Cap | $16.98B | $11.02B |
Volume | 1,456,900 | 6,609,157 |
Sector | Health | Fixed Income |
52-Week High | $157.36 | $105.36 |
52-Week Low | $82.26 | $91.34 |
Typical Hold Time | 12 Days | 60 Days |
Enterprise Value | $19.30B | — |
Dividend Yield | 0.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $152.16, down 0.94% on the day, but maintains a bullish technical trend with strong moving average signals and support near $149. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue remains stable around $2.9 billion, though net income margins have softened slightly. Recent news highlights product launches and strategic acquisitions, such as the Human Cell Design deal, to bolster its life sciences portfolio.
The outlook is supported by analyst optimism with a 51.72% buy rating and a consensus price target of $132.13, though the current price trades above this target. Key risks include premium valuation metrics, margin pressures, and exposure to macroeconomic headwinds. The stock's proximity to its 52-week high suggests momentum but warrants caution given rich multiples.
TLH (iShares 10-20 Year Treasury Bond ETF) trades at $92.11, up 0.72% with bearish technical signals from moving averages. The ETF shows unusually high trading volume, up 66% recently, amid a challenging bond market environment where 10-year Treasury yields have reached multi-decade highs. Recent dividend payments of $0.36-$0.38 reflect the fund's income-generating nature.
Outlook remains cautious as rising bond yields pressure long-term Treasury ETFs. Investment opportunity exists for income-focused investors seeking regular dividends, but risks include continued yield increases and Federal Reserve policy uncertainty. The bearish technical picture suggests near-term pressure on bond ETF valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About iShares 10 20 Year Treasury Bond ETF
TLH tracks the ICE U.S. Treasury 10-20 Year Bond Index, offering targeted exposure to intermediate-to-long term government debt. It serves as a middle ground between the 7-10 year (IEF) and 20+ year (TLT) ETFs, balancing yield and duration risk.
Read more on TLH →
